Hospitalist Doctors in Maryville, TN Accepting Medicare

4 Hospitalist doctors found. Showing 1 - 4

Dr. Deaver T Shattuck, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 907 E Lamar Alexander Pkwy, Maryville, TN 37804 Phone: 865-980-4897    Fax: 865-977-4722

Dr. Mark Ellison Green, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 365 Bmh Physicians Office Bldg, Maryville, TN 37804 Phone: 865-980-5360    Fax: 865-980-5356

Dr. David A Knoll, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 313 N Houston St, Maryville, TN 37801 Phone: 865-982-4824    Fax: 865-982-4825

Lukas Mathews, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 907 E Lamar Alexander Pkwy, Maryville, TN 37804 Phone: 865-980-4897    Fax: 865-977-4722

News Archive

Vitamin E may prevent cancer in patients with Cowden Syndrome

Cleveland Clinic researchers have discovered that vitamin E may prevent cancer in patients with an under-recognized genetic disorder.

NovAliX enters agreement to acquire Graffinity

NovAliX SAS today announced that it has entered into a definitive agreement to acquire a majority interest in Graffinity Pharmaceuticals GmbH of Heidelberg, Germany, a leading fragment based drug discovery services company.

FDA grants marketing clearance to Accuray's CyberKnife VSI System Lung Optimized Treatment

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market Lung Optimized Treatment, a new component of the CyberKnife® VSI™ System. The 510(k) clearance enables Accuray to provide physicians with greater flexibility in delivering radiosurgery treatments to patients with lung cancer, the most common and deadly cancer worldwide.

Effects of common anti-inflammatory drug and its degradation products on amphibians

A new study in Environmental Toxicology and Chemistry takes a harder look at the effects a common anti-inflammatory medication and its degradation products have on amphibians.

CLL aggressiveness linked to genetic variability

The genetic variability of a tumour could be a predictor for its aggressiveness: the greater the variability in gene expression, the more aggressive the tumour is likely to be. This is the hypothesis that the CNIO Structural Biology and Biocomputing Programme, led by Alfonso Valencia, is testing, after their findings on chronic lymphocytic leukaemia (CLL), now published in the journal Genome Medicine.

Read more Medical News

› Verified 1 days ago